CurrentEndo coverage · page 46 of 55

Diabetes, Obesity and Metabolism

Briefs 1,801–1,840 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab17 Dec 2023
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
Randomized controlled trialObesity
Diabetes Obes Metab15 Dec 2023
Safety, pharmacokinetics and pharmacodynamics of HRS ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
Randomized controlled trialT2D & other
Diabetes Obes Metab14 Dec 2023
Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis
Cohort studyT2D & other
Diabetes Obes Metab13 Dec 2023
Weight loss and treatment patterns in a real‐world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland ( ADDRESS study)
Cohort studyObesity
Diabetes Obes Metab12 Dec 2023
Effect of sodium‐glucose cotransporter‐2 inhibitors on myocardial infarction incidence: A systematic review and meta‐analysis of randomized controlled trials and cohort studies
Meta-analysisT2D & other
Diabetes Obes Metab12 Dec 2023
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Cohort studyT2D & other
Diabetes Obes Metab11 Dec 2023
Alanine to glycine ratio is a novel predictive biomarker for type 2 diabetes mellitus
Cohort studyT2D & other
Diabetes Obes Metab11 Dec 2023
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
Secondary analysisObesity
Diabetes Obes Metab11 Dec 2023
Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study)
Randomized controlled trialT2D & other
Diabetes Obes Metab11 Dec 2023
Establishment and validation of a prediction model for gestational diabetes
Diagnostic or prognostic studyDiabetes in pregnancy
Diabetes Obes Metab11 Dec 2023
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials
Meta-analysisT2D & other
Diabetes Obes Metab11 Dec 2023
Clinical effectiveness and cost‐impact after 2 years of a ketogenic diet and virtual coaching intervention for patients with diabetes
Cohort studyT2D & other
Diabetes Obes Metab30 Nov 2023
Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program
Secondary analysisT2D & other
Diabetes Obes Metab30 Nov 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD
Randomized controlled trialT2D & other
Diabetes Obes Metab29 Nov 2023
Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
Meta-analysisT2D & other
Diabetes Obes Metab29 Nov 2023
Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Meta-analysisT2D & other
Diabetes Obes Metab29 Nov 2023
Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
Meta-analysisEndocrine cancer
Diabetes Obes Metab28 Nov 2023
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial
Meta-analysisObesity
Diabetes Obes Metab27 Nov 2023
Does high‐normal blood pressure lead to excess cardiovascular disease events and deaths in Chinese people? A post‐hoc analysis of the 30‐year follow‐up of the Da Qing IGT and Diabetes Study
Secondary analysis
Diabetes Obes Metab23 Nov 2023
Association of five diet scores with severe NAFLD incidence: A prospective study from UK Biobank
Cohort studyLipids & liver
Diabetes Obes Metab23 Nov 2023
Associations between complexity of glucose time series and cognitive function in adults with type 2 diabetes
Cross-sectional studyT2D & other
Diabetes Obes Metab23 Nov 2023
Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial
Secondary analysisT2D & other
Diabetes Obes Metab23 Nov 2023
S odium‐glucose co‐transporter‐2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes
Cohort studyT2D & other
Diabetes Obes Metab23 Nov 2023
Sex‐specific associations between skeletal muscle mass and incident diabetes: A population‐based cohort study
Cohort studyT2D & other
Diabetes Obes Metab20 Nov 2023
Impact of a 4‐week intensive track and field training intervention on glycaemia in adolescents with type 1 diabetes: The ChilDFiT1 study
Randomized controlled trialT1D
Diabetes Obes Metab20 Nov 2023
Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study
Meta-analysisT2D & other
Diabetes Obes Metab14 Nov 2023
Non‐alcoholic fatty liver disease is associated with brain function disruption in type 2 diabetes patients without cognitive impairment
Cross-sectional studyT2D & other
Diabetes Obes Metab12 Nov 2023
Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: A meta‐analysis of randomized controlled trials
Meta-analysisDiabetes in pregnancy
Diabetes Obes Metab12 Nov 2023
A model‐informed approach to accelerate the clinical development of cofrogliptin ( HSK7653 ), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor
Meta-analysisT2D & other
Diabetes Obes Metab12 Nov 2023
Factors that determine glucose variability, defined by the coefficient of variation in continuous glucose monitoring values, in a Chinese population with type 2 diabetes
Cross-sectional studyTechnology
Diabetes Obes Metab12 Nov 2023
One‐hour post‐load glucose levels are associated with hepatic steatosis assessed by transient elastography
Cross-sectional studyLipids & liver
Diabetes Obes Metab9 Nov 2023
Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
Randomized controlled trialObesity
Diabetes Obes Metab8 Nov 2023
Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data
Cohort studyT2D & other
Diabetes Obes Metab8 Nov 2023
Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study
Randomized controlled trialT2D & other
Diabetes Obes Metab7 Nov 2023
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies
Secondary analysisT2D & other
Diabetes Obes Metab7 Nov 2023
Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: An age‐period‐cohort analysis
Cohort studyT2D & other
Diabetes Obes Metab6 Nov 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Secondary analysisObesity
Diabetes Obes Metab5 Nov 2023
Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes
Cohort studyTechnology
Diabetes Obes Metab5 Nov 2023
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE ‐3 study
Secondary analysisT2D & other
Diabetes Obes Metab3 Nov 2023
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy
Cohort studyComplications

All 2,200 Briefs in ExploreShowing Briefs 1,801–1,840 of 2,200, newest first